摘要
非诺贝特作为临床常见的降脂药,主要通过激活过氧化物酶体增殖物激活受体α(PPRAα)产生降脂作用。研究表明非诺贝特可以通过抑制肿瘤细胞增殖代谢、抑制新生血管形成、阻滞细胞周期、抑制细胞运动迁移、诱导细胞凋亡等来发挥抗肿瘤作用,且以上作用不全依赖PPRAα途径。非诺贝特不良反应小,有望辅助肿瘤临床内科治疗。
Fenofibrate is a common lipidlowing drug activating peroxisome proliferatoractivated receptor alpha (PPRAα). Recent studies have found that fenofibrate possesses anticancer properties. Its specific mechanisms include inhibiting cell metabolism and formation of new tumor vessels, arresting cell circle, weakening cell motility, and inducing cell apoptosis. Those properties are partly independent of PPRAα. Due to its low sideeffects, it′s hopefully to be used as an anticancer adjuvant drug.
出处
《国际肿瘤学杂志》
CAS
2017年第9期682-685,共4页
Journal of International Oncology
基金
苏州市科技计划(SYS201632)